By curing mild psoriasis with short-term anti-IL-17A therapy, investigators could reduce the cost of treating psoriasis and related diseases, including psoriatic arthritis, cardiovascular disease, and diabetes.Risankizumab consistently demonstrated higher efficacy compared to sukinumab in different patient groups. This evidence concerns the gene IL17A and psoriatic arthritis.